Abstract
There are hundreds of drugs in Phase III clinical trials, of which almost 200
of them may gain market approval from the FDA in the coming 5 years. Which
drugs will make it and how these drugs impact existing pharmaceutical markets
in terms of overall size and competitive share is one of the most difficult
forecasting projects in market research.
In this nearly 500-page analysis, Kalorama Information has compiled all the
relevant information about the candidates, their value, and their likely
impact. And we've made some predictions and estimates of the changing market
scenarios in five therapeutic areas.
In particular, this report examines over 500 drugs in Phase III clinical
trials and how these new products are expected to perform and affect existing
markets. The report looks at five therapeutic categories:
- Cardiovascular disease,
- Neuropsychotherapeutic disorders,
- Infectious disease,
- Cancer, and
- Others.
Market opportunity revenues are provided in each segment for approvals
anticipated from 2006 to 2010 with specific information related to likely 2006
approvals. For each segment, the report includes an
- Overview,
- Descriptions of products in phase III development,
- Number of approvals expected each year through 2010 by indication within
the segment,
- Market forecasts for those likely to be approved,
- Which major brands and marketers who are currently active the segment will
be affected by these likely new entrants, and
- What share of the segments these new drugs are likely to take.
This report is the only analysis of its kind available in syndicated form and
contains vital intelligence for strategic planners within the industry and
analysts and investors interested in the competitive dynamics in the years
ahead.
View Cart
